Second-line therapy in diffuse large B-cell lymphoma (DLBCL): treatment patterns and outcomes in older patients receiving outpatient chemotherapy

Mark D. Danese, Robert I. Griffiths, Michelle L. Gleeson, Tapashi Dalvi, Jingyi Li, Joseph R Mikhael, Robert Deeter, Martin Dreyling

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Using SEER-Medicare linked data we identified elderly patients diagnosed with diffuse large B-cell lymphoma (DLBCL) between January 2000 and December 2007 who received second-line outpatient chemotherapy for relapsed or refractory disease. Second-line regimens were classified into three mutually exclusive groups: aggressive, conventional, and palliative. Of the 632 (426 relapsed, 206 refractory) patients in the cohort, 27.8% received aggressive second-line therapy, 39.1% received conventional therapy, and 33.1% received palliative therapy. There were no differences in survival by type of therapy received, either for relapsed or refractory patients, although the patient risk profile differed significantly. However, duration of remission, male gender, and anemia at diagnosis were important predictors in relapsed patients, and male gender, B-symptoms, comorbidity burden, and poverty status were important predictors in refractory patients. Survival in elderly patients receiving second-line therapy remains poor, and the 24-month cost of all care exceeds $97,000. Patients would benefit from improved treatment options.

Original languageEnglish (US)
Pages (from-to)1-11
Number of pages11
JournalLeukemia and Lymphoma
DOIs
StateAccepted/In press - Sep 22 2016

Fingerprint

Lymphoma, Large B-Cell, Diffuse
Outpatients
Drug Therapy
Therapeutics
Survival
Poverty
Medicare
Palliative Care
Comorbidity
Anemia
Costs and Cost Analysis

Keywords

  • Cost
  • diffuse large B-cell lymphoma
  • elderly
  • second-line therapy
  • survival

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Second-line therapy in diffuse large B-cell lymphoma (DLBCL) : treatment patterns and outcomes in older patients receiving outpatient chemotherapy. / Danese, Mark D.; Griffiths, Robert I.; Gleeson, Michelle L.; Dalvi, Tapashi; Li, Jingyi; Mikhael, Joseph R; Deeter, Robert; Dreyling, Martin.

In: Leukemia and Lymphoma, 22.09.2016, p. 1-11.

Research output: Contribution to journalArticle

Danese, Mark D. ; Griffiths, Robert I. ; Gleeson, Michelle L. ; Dalvi, Tapashi ; Li, Jingyi ; Mikhael, Joseph R ; Deeter, Robert ; Dreyling, Martin. / Second-line therapy in diffuse large B-cell lymphoma (DLBCL) : treatment patterns and outcomes in older patients receiving outpatient chemotherapy. In: Leukemia and Lymphoma. 2016 ; pp. 1-11.
@article{ebcb260c86214721a8570647e9c7e539,
title = "Second-line therapy in diffuse large B-cell lymphoma (DLBCL): treatment patterns and outcomes in older patients receiving outpatient chemotherapy",
abstract = "Using SEER-Medicare linked data we identified elderly patients diagnosed with diffuse large B-cell lymphoma (DLBCL) between January 2000 and December 2007 who received second-line outpatient chemotherapy for relapsed or refractory disease. Second-line regimens were classified into three mutually exclusive groups: aggressive, conventional, and palliative. Of the 632 (426 relapsed, 206 refractory) patients in the cohort, 27.8{\%} received aggressive second-line therapy, 39.1{\%} received conventional therapy, and 33.1{\%} received palliative therapy. There were no differences in survival by type of therapy received, either for relapsed or refractory patients, although the patient risk profile differed significantly. However, duration of remission, male gender, and anemia at diagnosis were important predictors in relapsed patients, and male gender, B-symptoms, comorbidity burden, and poverty status were important predictors in refractory patients. Survival in elderly patients receiving second-line therapy remains poor, and the 24-month cost of all care exceeds $97,000. Patients would benefit from improved treatment options.",
keywords = "Cost, diffuse large B-cell lymphoma, elderly, second-line therapy, survival",
author = "Danese, {Mark D.} and Griffiths, {Robert I.} and Gleeson, {Michelle L.} and Tapashi Dalvi and Jingyi Li and Mikhael, {Joseph R} and Robert Deeter and Martin Dreyling",
year = "2016",
month = "9",
day = "22",
doi = "10.1080/10428194.2016.1228924",
language = "English (US)",
pages = "1--11",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",

}

TY - JOUR

T1 - Second-line therapy in diffuse large B-cell lymphoma (DLBCL)

T2 - treatment patterns and outcomes in older patients receiving outpatient chemotherapy

AU - Danese, Mark D.

AU - Griffiths, Robert I.

AU - Gleeson, Michelle L.

AU - Dalvi, Tapashi

AU - Li, Jingyi

AU - Mikhael, Joseph R

AU - Deeter, Robert

AU - Dreyling, Martin

PY - 2016/9/22

Y1 - 2016/9/22

N2 - Using SEER-Medicare linked data we identified elderly patients diagnosed with diffuse large B-cell lymphoma (DLBCL) between January 2000 and December 2007 who received second-line outpatient chemotherapy for relapsed or refractory disease. Second-line regimens were classified into three mutually exclusive groups: aggressive, conventional, and palliative. Of the 632 (426 relapsed, 206 refractory) patients in the cohort, 27.8% received aggressive second-line therapy, 39.1% received conventional therapy, and 33.1% received palliative therapy. There were no differences in survival by type of therapy received, either for relapsed or refractory patients, although the patient risk profile differed significantly. However, duration of remission, male gender, and anemia at diagnosis were important predictors in relapsed patients, and male gender, B-symptoms, comorbidity burden, and poverty status were important predictors in refractory patients. Survival in elderly patients receiving second-line therapy remains poor, and the 24-month cost of all care exceeds $97,000. Patients would benefit from improved treatment options.

AB - Using SEER-Medicare linked data we identified elderly patients diagnosed with diffuse large B-cell lymphoma (DLBCL) between January 2000 and December 2007 who received second-line outpatient chemotherapy for relapsed or refractory disease. Second-line regimens were classified into three mutually exclusive groups: aggressive, conventional, and palliative. Of the 632 (426 relapsed, 206 refractory) patients in the cohort, 27.8% received aggressive second-line therapy, 39.1% received conventional therapy, and 33.1% received palliative therapy. There were no differences in survival by type of therapy received, either for relapsed or refractory patients, although the patient risk profile differed significantly. However, duration of remission, male gender, and anemia at diagnosis were important predictors in relapsed patients, and male gender, B-symptoms, comorbidity burden, and poverty status were important predictors in refractory patients. Survival in elderly patients receiving second-line therapy remains poor, and the 24-month cost of all care exceeds $97,000. Patients would benefit from improved treatment options.

KW - Cost

KW - diffuse large B-cell lymphoma

KW - elderly

KW - second-line therapy

KW - survival

UR - http://www.scopus.com/inward/record.url?scp=84988624257&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84988624257&partnerID=8YFLogxK

U2 - 10.1080/10428194.2016.1228924

DO - 10.1080/10428194.2016.1228924

M3 - Article

C2 - 27659997

AN - SCOPUS:84988624257

SP - 1

EP - 11

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

ER -